Agoracom Blog Home

Archive for the ‘Tetra Bio-Pharma Inc.’ Category

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Goes After the #Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with #SantéCannabis

Posted by AGORACOM-JC at 8:29 AM on Thursday, October 26th, 2017

Tbp large new

  • Announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market
  • vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians and pharmacists to prescribe and dispense these medicines to patients in need

OTTAWA, ONTARIO–(Oct. 26, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

Last year Tetra launched several drug development programs to commercialize cannabis-based prescription drugs making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians and pharmacists to prescribe and dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are hesitant to support the use of these products because of the lack of data supporting its medical use; even though healthcare professionals have to offer the best available care to patients, they also need to ensure that the treatment dispensed by pharmacists does no harm.

Since 2015, the Canadian cannabis oil market has grown from below 600 kg in the first quarter (Jan-Mar) of 2016 to over 6000 kg in the same first quarter of 2017, and it is expected that this market will continue to show significant growth according to a July 26, 2017 report by Eight Capital. Based on an estimated average sales price of $75-100 per 60 ml for cannabis oil, the 2017 global cannabis oil sales in Canada could exceed 30 million dollars.

According to Tetra’s Chief Executive Officer (CEO), Bernard Fortier,” Tetra is in a good position to penetrate this market. We have been preparing for months how to differentiate ourselves within this market while maintaining our corporate vision of an evidence-based approach. The cannabis oil market will be no different for Tetra. The corporation is dedicated to providing evidence and supporting physicians and other healthcare professionals while making cannabis accessible to their patients. We are on target to initiate our sales strategy by March 2018 to carve out a solid position within the Canadian market. We expect to generate revenues in the cannabis oil market in 2018 and we will grow these revenues as physicians become aware of our scientific approach and patient care programs. Based on a conservative market penetration estimate, we are targeting to grow our share of the cannabis oil business to over 1 million in revenues by 2019.”

Furthermore, Tetra is announcing that it is supporting a post-marketing study (phase 4 clinical trial) of the use of cannabis oil in the treatment of chronic pain. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population. Tetra will be supporting Santé Cannabis in this important endeavor with its internal regulatory and scientific team. Data generated by this study will help Tetra’s medical team in educating physicians on the potential of cannabis oils to treat patients suffering from chronic pain. Once completed, this trial will allow Tetra to penetrate even further into the cannabis oil market making it one of the key players as it continues to grow its share of this over 30-million-plus dollar market.

Tetra’s scientific team is also supporting the sales strategy by initiating a safety and pharmacokinetic study in healthy volunteers (phase 1 clinical trial) to characterize the safe use of these cannabis oil medicines in humans. Combined with the study in patients suffering from chronic pain, Tetra will have a solid and credible position in the medical cannabis oil market. Dr. Chamberland, Tetra’s Chief Scientific Officer (CSO), commented that” physicians are concerned about the potential side effects and well-being of patients using cannabis oil. It is this type of data that continues to allow Tetra to differentiate itself in the medical cannabis market as we become leader in the field. Over and over, physicians and pharmacists welcome the pharmaceutical approach used by Tetra as it is a proven model for bringing safe and efficacious therapies to patients. Patients are expecting their healthcare professionals to treat cannabis like a medicine and help ensure that they safely consume these products. This expectation from patients will soon be fulfilled by Tetra’s strategic approach to patient care.”.

From a business point of view, these studies are part of the sales and marketing strategy required to effectively penetrate a physician-pharmacist product market. The outcome of these studies will also support Tetra’s overall drug development strategy and it is expected that this will allow Tetra to reduce the overall time-to-market for a number of its cannabis-based prescription drugs. The company will also use this data to create novel new products that will allow Tetra to further increase its revenues in the cannabis oil market.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210
www.tetrabiopharma.com

Tags: , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Goes After the #Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with #SantéCannabis

FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Posted by AGORACOM-JC at 11:38 AM on Tuesday, October 24th, 2017

WHY TETRA BIO-PHARMA?

 

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected

Tags: , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Posted by AGORACOM-JC at 8:07 AM on Thursday, October 19th, 2017

Tbp large new

  • Announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
  • Will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis

OTTAWA, ONTARIO–(Oct. 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Dr. Jourdain will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis. Dr. Jourdain has extensive training and knowledge in pharmacology and neuroscience and is a critical addition to the Tetra team. An important part of his role will be to support the sales of Rx Princepsâ„¢ through New Brunswick and the Maritimes, as well as in Quebec, by presenting the safety, pharmacokinetic, and pharmacodynamic data gathered in Tetra’s Phase 1 clinical trial of PPP001.

“The addition of Dr. Jourdain demonstrates our strategic intention to position Tetra Bio-Pharma as the leader in the medical cannabis market. Bringing an individual with the level of scientific knowledge and expertise of Dr. Jourdain shows our organization’s commitment to the medical community; they can continue to count on Tetra Bio-Pharma as a credible and professional source of information for their practice and their patients. We are looking forward to further developing relationships with opinion leaders in the field as we continue to advance our clinical program and work on bringing new drug alternatives for patients and their treating healthcare professionals.” states Dr. Guy Chamberland, Chief Scientific Officer of Tetra.

Tetra also reveals today its new logo and corporate image, thereby aligning its corporate image with its medical strategy. The evolution of The Company’s image highlights Tetra’s objective to be the reference for the medical community in prescribed cannabinoids’ safety, efficacy, and quality. Tetra is focused on bringing to the ACMPR market the highest quality medical cannabis; the Company remains committed to receive the first drug approval from Health Canada’s Therapeutic Products Directorate for a medical cannabis drug.

About RxPrincepsâ„¢:

Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princepsâ„¢ will soon be available across Canada, through our partner Aphria’s customer service, for patients who have a prescription from their physicians.

About Dr. Vincent Jourdain, Ph.D.:

Dr. V. Jourdain, Ph.D. is a graduate from the pharmacy program at Laval University in Quebec City, where he specialized in neurological disorders. He completed his postdoctoral training at the Feinstein Institute for Medical Research in New York. He used brain imaging to study metabolic and neurovascular changes in Parkinson’s disease and pharmacologically-induced side effects. Dr. Jourdain possesses a broad, yet specialized, knowledge in Neurology and accumulated close to 10 years of experience in basic and clinical research. He published over 15 peer-review publications and won several awards and scholarships.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Tetra Bio-Pharma $TBP.ca Signs Agreement with Partner Aphria $APH.ca to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

Posted by AGORACOM-JC at 8:12 AM on Wednesday, October 18th, 2017

Tbp large new

  • Will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR)
  • Signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials

OTTAWA, ONTARIO- (Oct. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.

Rx Princepsâ„¢ will be a new option for doctors who want to prescribe medical cannabis, while ensuring that their patients will receive a consistent and high-quality product. Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada, thereby complying with the quality standards Tetra wants to bring to the medical community and its patients.

Rx Princepsâ„¢ will be a new therapeutic option not only for the 19% of adults who suffer from chronic pain in Canada, but also for the more than 200,000 patients already registered under the ACMPR program. Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now prepared to enter this lucrative market.

“Our objective is to position ourselves as the reference for the medical community in the prescription of medical cannabis, and gain our growing share of that market in the years to come. We believe that we are bringing additional value to patients, physicians and other key healthcare professionals involved in treating at-need patients. We are ready to launch our first medical product, and we couldn’t be more pleased to do it with a partner such as Aphria, which has demonstrated their commitment to our vision of offering a medical product of the highest quality. Our team is dedicated to make this part of our business a very successful one, bringing value to our investors in the process. Being able to generate revenue to support our operations is an important step for Tetra Bio-Pharma,” says Bernard Fortier, CEO of Tetra Bio-Pharma.

About Rx Princepsâ„¢:

Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princepsâ„¢ will be available across Canada, through Aphria’s customer service, for patients who have a prescription from their physicians.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information about Aphria, please contact:
Nina Godard – Edelman
416-455-6324
[email protected]

Vic Neufeld, President & CEO
1-844-427-4742

For further information about Tetra Bio-Pharma
and Rx Princeps(TM), please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

Tags: , , ,
Posted in Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Signs Agreement with Partner Aphria $APH.ca to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

Invested in INSYS Therapeutics $INSY ? Tetra Bio-Pharma $TBP.ca is the Only pharmaceutical company to have clinical studies for smoked marijuana

Posted by AGORACOM-JC at 5:01 PM on Friday, October 13th, 2017

Tbp large new

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.
  • Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Invested in INSYS Therapeutics $INSY ? Tetra Bio-Pharma $TBP.ca is the Only pharmaceutical company to have clinical studies for smoked marijuana

Tetra Bio-Pharma $TBP.ca Selected to Present at Prestigious #BIOInvestorForum In San Francisco October 17-18

Posted by AGORACOM-JC at 5:24 PM on Wednesday, October 4th, 2017

Tbp large new

  • Announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel
  • BIO Investor Forum is one of the premiere Investor/Bio-Partnering events providing access to more than 125 investment funds, 175 BioPharmaceutical companies and 800 delegates from all over the world

OTTAWA, ONTARIO–( Oct. 4, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel. Robert (Bob) Bechard, Vice-President, Finance and Business Development of Tetra will present on Tuesday the 17th at 4:00pm Pacific Time (7:00pm Eastern Time). The presentation will be available live via webcast.

BIO Investor Forum is one of the premiere Investor/Bio-Partnering events providing access to more than 125 investment funds, 175 BioPharmaceutical companies and 800 delegates from all over the world, giving Tetra an excellent opportunity to present its robust product pipeline that is chasing multi-billion dollar markets including cancer pain, neuropathic pain, chemo induced vomiting and nausea, as well as dry eye, eye pain, and chronic pain. Tetra is the only company that has successfully run clinical trials using a smokable cannabis product recognized by Health Canada and the Food and Drug Administration (USA) and has generated Phase I results that demonstrated excellent bioavailability and safety data which has created great interest from pharmaceutical companies and Bio-Pharma investors. In addition to presenting Tetra will be holding one-on-one Investor and Partnering meetings to carefully identify future Investors and Partners and will also be advancing its discussions with partners met at previous conferences.

“It is indeed an honor to have been selected by BIO Investor Forum to present at this most prestigious conference. Our selection was based on the strength and innovation of our pipeline, with a potential of bringing novel therapies to huge number of patients and pursuing billion dollar markets. Events like BIO Investor enable us to get in contact with 100s of investors, companies, and delegates in a very short period of time, allowing us to cost-effectively spread the word on the enormous potential of our business model,” said Bernard Fortier, CEO of Tetra Bio-Pharma. “We strongly believe in the future potential of our business strategy as we build Tetra into a global leader in cannabinoid-based drug discovery and development.”

A link to the live audio webcast will be available on Tetra’s website at http://tetrabiopharma.com/investors/presentations/default.aspx. The webcast will be archived for three months.

Furthermore, Tetra announces that on October 3rd, 2017, in accordance with the Company’s stock option plan and subject to the approval of the Toronto Stock Exchange, the Board of Directors granted an aggregate of 1,400,000 incentive stock options (“options”) to its officers and directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.69 per share until October 3, 2018 and October 3, 2021. The options and any common shares issued upon exercise thereof will be subject to a four-month resale restriction from the date of grant.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]
www.tetrabiopharma.com

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Selected to Present at Prestigious #BIOInvestorForum In San Francisco October 17-18

Invested in INSYS Therapeutics $INSY ? Tetra Bio-Pharma $TBP.ca is the Only pharmaceutical company to have clinical studies for smoked marijuana

Posted by AGORACOM-JC at 11:20 AM on Wednesday, October 4th, 2017

Tbp large new

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Invested in INSYS Therapeutics $INSY ? Tetra Bio-Pharma $TBP.ca is the Only pharmaceutical company to have clinical studies for smoked marijuana

Invested in #MMJ stocks like Cannagrow $CGRW Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Posted by AGORACOM-JC at 2:06 PM on Monday, September 25th, 2017

Tbp large new

TBP: TSX-V

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Invested in #MMJ stocks like Cannagrow $CGRW Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Tetra Bio-Pharma $TBP.ca to engage in co-development and distribution partnership with major healthcare specialty distributor

Posted by AGORACOM-JC at 8:19 AM on Wednesday, September 20th, 2017

Tbp large new

  • Announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry
  • Privately-owned partner has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals
  • First product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018
  • Tetra and its partner will be tapping into the overall Over-The-Counter topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis

OTTAWA, ONTARIO–(Sept. 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to over 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners, including the USA.

Tetra and its partner are working together to develop a new line of products, leveraging Tetra’s clinical and product development expertise. The first product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018. Tetra and its partner will be tapping into the overall Over-The-Counter (OTC) topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis. Both companies are expecting to grab a share if the specialized OTC topical analgesics market in a short period of time and could see sales generated from this distribution channel reaching $3 million for Canada in the 1st year. Since the initial launch phase will be focused on the Canadian market, further guidance will be provided as Tetra’s partner gets ready to launch in the US.

« We’re excited to enter this specialized market as there is a significant need for our clinical expertise in product development. This partnership opens a new distribution channel for our pharmaceutical retail division not only in Canada, but also worldwide through their active partners in the US and Europe. Tetra remains committed and is actively developing partnerships to generate a significant revenue stream. This partnership demonstrates our team’s focus and dedication in accelerating our commercialization strategy towards selling a specialized line of products in our pharmaceutical retail business, » comments Bernard Fortier, CEO of Tetra Bio-Pharma.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice-President Marketing & Communication
1 (514) 360-8040 Ext. 210
[email protected]
www.tetrabiopharma.com

Tags: , , , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca to engage in co-development and distribution partnership with major healthcare specialty distributor

Invested in #MMJ stocks like Cannagrow $CGRW ? Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Posted by AGORACOM-JC at 12:36 PM on Thursday, September 14th, 2017

Tbp large new

TBP: TSX-V

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Tags: , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Invested in #MMJ stocks like Cannagrow $CGRW ? Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

« Older Entries
Newer Entries »